News and updates — Page 25 of 29 — German Market Access

ITC was accepted and improved additional benefit rating

In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a

The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It

If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,

This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural

Did you know that some hospital methods are not covered by SHI funds? In Germany, non-drug interventions are assessed as methods. Methods